Imagine the possibilities: What the SYD-101 CRL means for myopia care

Recently, my family has been affected by a devastating, rare progressive neurodegenerative disease. There is no approved treatment, no road map, no reliable option to slow its course. The experience is, at times, hopeless. But it also sharpens something else: a deep awareness of what it means when medicine does have options and when it does not.

As parents and clinicians, we want the best for our children and our patients. Evidence-based choice should be the natural choice. And yet, in myopia management, we find ourselves in a paradox: Science is there, but access is not.

Off-label low-dose atropine has emerged as a cornerstone of modern myopia control. Its efficacy is well-documented, its safety profile is favorable, and its implementation in clinical practice is straightforward. A growing body of evidence supports its role in slowing pediatric myopia progression. Against this backdrop, the potential regulatory approval of SYD-101 (atropine 0.01%; Sydnexis) represented more than just another product. It represented access, consistency, and possibility for millions of children.

So when the FDA issued a complete response letter (CRL) in fall 2025 declining approval, it raised a fundamental question: When evidence exists, why does access not follow?

Let’s take a closer look

Sydnexis conducted one of the largest pediatric myopia trials to date, enrolling more than 800 children in the US. The study met its primary end points under FDA guidance. However, the CRL cited concerns about clinical meaningfulness, pointing to findings such as a modest mean difference in refractive error progression at 36 months. Notably, the FDA did not raise concerns regarding safety or manufacturing quality.

This distinction matters

The absence of safety concerns addresses the most common and most important question parents ask: Is this safe for my child? The answer appears reassuring. Yet the regulatory decision depended on how benefit was measured across a diverse study population.

And that is where the nuance lies

Myopia is not a uniform condition. It is a complex, dynamic process influenced by age, genetics, environment, and behavior. Younger children tend to experience progression more rapidly and often derive the greatest benefit from intervention. Similarly, those with fast progression may respond differently than those with slower disease trajectories.

Publicly discussed analyses at the 2026 American Association for Pediatric Ophthalmology and Strabismus Annual Meeting about the STAR trial of SYD-101 suggest that when SYD-101 outcomes are stratified, the signal becomes clearer:

• Greater efficacy in younger age groups (3-12 years)
• Meaningful reductions (~76% reduction at 12 months; ~56% reduction at 36 months) in children with faster progression (>0.5 D/year)
• Stronger response in mild to moderate baseline myopia (–0.50 to –3.00 D)

When viewed through this lens, averaging outcomes across all participants may dilute clinically relevant benefits in the very populations we aim to treat most aggressively: younger children, those with fast disease progression, and those in earlier myopia stages.

This raises an important question for regulators and clinicians alike: Should a therapy be judged solely on aggregate outcomes or on its ability to meaningfully benefit well-defined patient subgroups?

Meanwhile, the practical implications of the CRL are immediate. In the United States, we continue to rely on compounded low-dose atropine. These formulations vary in stability, pH, and consistency. Families may receive drops that require refrigeration or freezing during shipment. Dosing inaccuracies can occur. Costs are often out-of-pocket and variable.

This is not a criticism of compounding pharmacies. It reflects a system filling a gap.

A regulated, FDA-approved formulation would offer something fundamentally different: standardized dosing, verified stability, consistent comfort, and the potential for broader insurance coverage. It would establish a benchmark, a gold standard that benefits both practitioners and patients.

Why does this matter?

Myopia management is not one-size-fits-all. Some patients respond best to optical interventions such as peripheral defocus contact lenses or glasses. Others benefit from pharmacologic therapy. Many require a combination approach or a transition between modalities over time.

To deliver truly personalized care, clinicians need a full toolbox and patients need access.

Cost remains a critical barrier. Too many families are aware of myopia control options but decline treatment due to affordability. A regulated therapy has the potential to shift this landscape to expand access and improve adherence through increased trust and coverage.

Ultimately, this conversation extends beyond a single drug.

It is about how we define meaningful benefits. It is about whether safety, consistency, and subgroup efficacy are given appropriate weight in regulatory decisions. It is also about whether clinicians are empowered to apply evidence in ways that reflect real-world patient variability.

For my family member who is facing a rare disease, there are no options. That absence is profound.

In myopia care, we are not in that position. We have evidence. We have tools. We have momentum. Imagine the possibilities if we align them.

I urge regulators to take a comprehensive view: one that prioritizes safety, recognizes differential efficacy across patient populations, and acknowledges the realities of clinical practice. Let clinicians determine the best course of care. Let parents have informed choices that are accessible and affordable.

When it comes to our children, doing better is not optional.

It is essential.